Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 149

1.

TDP1 suppresses mis-joining of radiomimetic DNA double-strand breaks and cooperates with Artemis to promote optimal nonhomologous end joining.

Kawale AS, Akopiants K, Valerie K, Ruis B, Hendrickson EA, Huang SN, Pommier Y, Povirk LF.

Nucleic Acids Res. 2018 Sep 28;46(17):8926-8939. doi: 10.1093/nar/gky694.

2.

The brain-penetrant clinical ATM inhibitor AZD1390 radiosensitizes and improves survival of preclinical brain tumor models.

Durant ST, Zheng L, Wang Y, Chen K, Zhang L, Zhang T, Yang Z, Riches L, Trinidad AG, Fok JHL, Hunt T, Pike KG, Wilson J, Smith A, Colclough N, Reddy VP, Sykes A, Janefeldt A, Johnström P, Varnäs K, Takano A, Ling S, Orme J, Stott J, Roberts C, Barrett I, Jones G, Roudier M, Pierce A, Allen J, Kahn J, Sule A, Karlin J, Cronin A, Chapman M, Valerie K, Illingworth R, Pass M.

Sci Adv. 2018 Jun 20;4(6):eaat1719. doi: 10.1126/sciadv.aat1719. eCollection 2018 Jun.

3.

Orally Bioavailable and Blood-Brain Barrier-Penetrating ATM Inhibitor (AZ32) Radiosensitizes Intracranial Gliomas in Mice.

Karlin J, Allen J, Ahmad SF, Hughes G, Sheridan V, Odedra R, Farrington P, Cadogan EB, Riches LC, Garcia-Trinidad A, Thomason AG, Patel B, Vincent J, Lau A, Pike KG, Hunt TA, Sule A, Valerie NCK, Biddlestone-Thorpe L, Kahn J, Beckta JM, Mukhopadhyay N, Barlaam B, Degorce SL, Kettle J, Colclough N, Wilson J, Smith A, Barrett IP, Zheng L, Zhang T, Wang Y, Chen K, Pass M, Durant ST, Valerie K.

Mol Cancer Ther. 2018 Aug;17(8):1637-1647. doi: 10.1158/1535-7163.MCT-17-0975. Epub 2018 May 16.

4.

DNA Damage Response in Human Stem Cells and Neural Descendants.

Beckta JM, Adams BR, Valerie K.

Methods Mol Biol. 2017;1599:375-390. doi: 10.1007/978-1-4939-6955-5_27.

PMID:
28477133
5.

Correction: Mutation of the BRCA1 SQ-cluster results in aberrant mitosis, reduced homologous recombination, and a compensatory increase in non-homologous end joining.

Beckta JM, Dever SM, Gnawali N, Khalil A, Sule A, Golding SE, Rosenberg E, Narayanan A, Kehn-Hall K, Xu B, Povirk LF, Valerie K.

Oncotarget. 2016 Sep 6;7(36):58716. doi: 10.18632/oncotarget.11846. No abstract available.

6.

Inhibition of radiation-induced glioblastoma invasion by genetic and pharmacological targeting of MDA-9/Syntenin.

Kegelman TP, Wu B, Das SK, Talukdar S, Beckta JM, Hu B, Emdad L, Valerie K, Sarkar D, Furnari FB, Cavenee WK, Wei J, Purves A, De SK, Pellecchia M, Fisher PB.

Proc Natl Acad Sci U S A. 2017 Jan 10;114(2):370-375. doi: 10.1073/pnas.1616100114. Epub 2016 Dec 23.

7.

Click synthesis of a polyamidoamine dendrimer-based camptothecin prodrug.

Zolotarskaya OY, Xu L, Valerie K, Yang H.

RSC Adv. 2015;5(72):58600-58608. Epub 2015 Jun 29.

8.

Mutation of the BRCA1 SQ-cluster results in aberrant mitosis, reduced homologous recombination, and a compensatory increase in non-homologous end joining.

Beckta JM, Dever SM, Gnawali N, Khalil A, Sule A, Golding SE, Rosenberg E, Narayanan A, Kehn-Hall K, Xu B, Povirk LF, Valerie K.

Oncotarget. 2015 Sep 29;6(29):27674-87. doi: 10.18632/oncotarget.4876. Erratum in: Oncotarget. 2016 Sep 6;7(36):58716.

9.

BRCA1 functions as a novel transcriptional cofactor in HIV-1 infection.

Guendel I, Meltzer BW, Baer A, Dever SM, Valerie K, Guo J, Wu Y, Kehn-Hall K.

Virol J. 2015 Mar 6;12:40. doi: 10.1186/s12985-015-0266-8.

10.

Peptide library approach to uncover phosphomimetic inhibitors of the BRCA1 C-terminal domain.

White ER, Sun L, Ma Z, Beckta JM, Danzig BA, Hacker DE, Huie M, Williams DC, Edwards RA, Valerie K, Glover JN, Hartman MC.

ACS Chem Biol. 2015 May 15;10(5):1198-208. doi: 10.1021/cb500757u. Epub 2015 Feb 5.

11.

Revisiting p53 for cancer-specific chemo- and radiotherapy: ten years after.

Beckta JM, Ahmad SF, Yang H, Valerie K.

Cell Cycle. 2014;13(5):710-3. doi: 10.4161/cc.28108. Epub 2014 Feb 7. Review.

12.

Autophagy and radiosensitization in cancer.

Sharma K, Goehe R, Beckta JM, Valerie K, Gewirtz DA.

EXCLI J. 2014 Feb 25;13:178-91. eCollection 2014. Review.

13.

Tracking the processing of damaged DNA double-strand break ends by ligation-mediated PCR: increased persistence of 3'-phosphoglycolate termini in SCAN1 cells.

Akopiants K, Mohapatra S, Menon V, Zhou T, Valerie K, Povirk LF.

Nucleic Acids Res. 2014 Mar;42(5):3125-37. doi: 10.1093/nar/gkt1347. Epub 2013 Dec 25.

14.

Ligand modulation of a dinuclear platinum compound leads to mechanistic differences in cell cycle progression and arrest.

Menon VR, Peterson EJ, Valerie K, Farrell NP, Povirk LF.

Biochem Pharmacol. 2013 Dec 15;86(12):1708-20. doi: 10.1016/j.bcp.2013.10.012. Epub 2013 Oct 24.

15.

Mitochondrial localized Stat3 promotes breast cancer growth via phosphorylation of serine 727.

Zhang Q, Raje V, Yakovlev VA, Yacoub A, Szczepanek K, Meier J, Derecka M, Chen Q, Hu Y, Sisler J, Hamed H, Lesnefsky EJ, Valerie K, Dent P, Larner AC.

J Biol Chem. 2013 Oct 25;288(43):31280-8. doi: 10.1074/jbc.M113.505057. Epub 2013 Sep 9.

16.

The Influence of Hypoxia and pH on Bioluminescence Imaging of Luciferase-Transfected Tumor Cells and Xenografts.

Khalil AA, Jameson MJ, Broaddus WC, Lin PS, Dever SM, Golding SE, Rosenberg E, Valerie K, Chung TD.

Int J Mol Imaging. 2013;2013:287697. doi: 10.1155/2013/287697. Epub 2013 Jul 7.

17.

ATM kinase inhibition preferentially sensitizes p53-mutant glioma to ionizing radiation.

Biddlestone-Thorpe L, Sajjad M, Rosenberg E, Beckta JM, Valerie NC, Tokarz M, Adams BR, Wagner AF, Khalil A, Gilfor D, Golding SE, Deb S, Temesi DG, Lau A, O'Connor MJ, Choe KS, Parada LF, Lim SK, Mukhopadhyay ND, Valerie K.

Clin Cancer Res. 2013 Jun 15;19(12):3189-200. doi: 10.1158/1078-0432.CCR-12-3408. Epub 2013 Apr 25.

18.

Subcutaneous administration of D-luciferin is an effective alternative to intraperitoneal injection in bioluminescence imaging of xenograft tumors in nude mice.

Khalil AA, Jameson MJ, Broaddus WC, Chung TD, Golding SE, Dever SM, Rosenberg E, Valerie K.

ISRN Mol Imaging. 2013;2013. pii: 689279.

19.

Two- and three-dimensional live cell imaging of DNA damage response proteins.

Beckta JM, Henderson SC, Valerie K.

J Vis Exp. 2012 Sep 28;(67). pii: 4251. doi: 10.3791/4251.

20.

Synthesis of water-soluble camptothecin-polyoxetane conjugates via click chemistry.

Zolotarskaya OY, Wagner AF, Beckta JM, Valerie K, Wynne KJ, Yang H.

Mol Pharm. 2012 Nov 5;9(11):3403-8. doi: 10.1021/mp3005066. Epub 2012 Oct 23.

21.

The autophagy-senescence connection in chemotherapy: must tumor cells (self) eat before they sleep?

Goehe RW, Di X, Sharma K, Bristol ML, Henderson SC, Valerie K, Rodier F, Davalos AR, Gewirtz DA.

J Pharmacol Exp Ther. 2012 Dec;343(3):763-78. doi: 10.1124/jpet.112.197590. Epub 2012 Aug 27.

22.

Dynamic inhibition of ATM kinase provides a strategy for glioblastoma multiforme radiosensitization and growth control.

Golding SE, Rosenberg E, Adams BR, Wignarajah S, Beckta JM, O'Connor MJ, Valerie K.

Cell Cycle. 2012 Mar 15;11(6):1167-73. doi: 10.4161/cc.11.6.19576. Epub 2012 Mar 15.

23.

BRCA1-directed, enhanced and aberrant homologous recombination: mechanism and potential treatment strategies.

Dever SM, White ER, Hartman MC, Valerie K.

Cell Cycle. 2012 Feb 15;11(4):687-94. doi: 10.4161/cc.11.4.19212. Epub 2012 Feb 15. Review.

24.

Nanomaterial-mediated CNS delivery of diagnostic and therapeutic agents.

Biddlestone-Thorpe L, Marchi N, Guo K, Ghosh C, Janigro D, Valerie K, Yang H.

Adv Drug Deliv Rev. 2012 May 15;64(7):605-13. doi: 10.1016/j.addr.2011.11.014. Epub 2011 Dec 8. Review.

25.

MRE11 and ATM AKTivate pro-survival signaling.

Golding SE, Valerie K.

Cell Cycle. 2011 Oct 1;10(19):3227. doi: 10.4161/cc.10.19.17048. Epub 2011 Oct 1. No abstract available.

26.

DNA double-strand break - induced pro-survival signaling.

Hawkins AJ, Golding SE, Khalil A, Valerie K.

Radiother Oncol. 2011 Oct;101(1):13-7. doi: 10.1016/j.radonc.2011.05.074. Epub 2011 Jul 2. Review.

27.

Mutations in the BRCT binding site of BRCA1 result in hyper-recombination.

Dever SM, Golding SE, Rosenberg E, Adams BR, Idowu MO, Quillin JM, Valerie N, Xu B, Povirk LF, Valerie K.

Aging (Albany NY). 2011 May;3(5):515-32.

28.

ATM-dependent ERK signaling via AKT in response to DNA double-strand breaks.

Khalil A, Morgan RN, Adams BR, Golding SE, Dever SM, Rosenberg E, Povirk LF, Valerie K.

Cell Cycle. 2011 Feb 1;10(3):481-91. Epub 2011 Feb 1.

29.

ATM-independent, high-fidelity nonhomologous end joining predominates in human embryonic stem cells.

Adams BR, Hawkins AJ, Povirk LF, Valerie K.

Aging (Albany NY). 2010 Sep;2(9):582-96.

30.

Dynamic dependence on ATR and ATM for double-strand break repair in human embryonic stem cells and neural descendants.

Adams BR, Golding SE, Rao RR, Valerie K.

PLoS One. 2010 Apr 2;5(4):e10001. doi: 10.1371/journal.pone.0010001.

31.

Improved ATM kinase inhibitor KU-60019 radiosensitizes glioma cells, compromises insulin, AKT and ERK prosurvival signaling, and inhibits migration and invasion.

Golding SE, Rosenberg E, Valerie N, Hussaini I, Frigerio M, Cockcroft XF, Chong WY, Hummersone M, Rigoreau L, Menear KA, O'Connor MJ, Povirk LF, van Meter T, Valerie K.

Mol Cancer Ther. 2009 Oct;8(10):2894-902. doi: 10.1158/1535-7163.MCT-09-0519. Epub 2009 Oct 6.

32.

Tyrosyl-DNA phosphodiesterase and the repair of 3'-phosphoglycolate-terminated DNA double-strand breaks.

Zhou T, Akopiants K, Mohapatra S, Lin PS, Valerie K, Ramsden DA, Lees-Miller SP, Povirk LF.

DNA Repair (Amst). 2009 Aug 6;8(8):901-11. doi: 10.1016/j.dnarep.2009.05.003. Epub 2009 Jun 7.

33.

Requirement for XLF/Cernunnos in alignment-based gap filling by DNA polymerases lambda and mu for nonhomologous end joining in human whole-cell extracts.

Akopiants K, Zhou RZ, Mohapatra S, Valerie K, Lees-Miller SP, Lee KJ, Chen DJ, Revy P, de Villartay JP, Povirk LF.

Nucleic Acids Res. 2009 Jul;37(12):4055-62. doi: 10.1093/nar/gkp283. Epub 2009 May 6.

34.

Nuclear factor I isoforms regulate gene expression during the differentiation of human neural progenitors to astrocytes.

Wilczynska KM, Singh SK, Adams B, Bryan L, Rao RR, Valerie K, Wright S, Griswold-Prenner I, Kordula T.

Stem Cells. 2009 May;27(5):1173-81. doi: 10.1002/stem.35.

35.

Pro-survival AKT and ERK signaling from EGFR and mutant EGFRvIII enhances DNA double-strand break repair in human glioma cells.

Golding SE, Morgan RN, Adams BR, Hawkins AJ, Povirk LF, Valerie K.

Cancer Biol Ther. 2009 Apr;8(8):730-8. Epub 2009 Apr 22.

36.

In vitro complementation of Tdp1 deficiency indicates a stabilized enzyme-DNA adduct from tyrosyl but not glycolate lesions as a consequence of the SCAN1 mutation.

Hawkins AJ, Subler MA, Akopiants K, Wiley JL, Taylor SM, Rice AC, Windle JJ, Valerie K, Povirk LF.

DNA Repair (Amst). 2009 May 1;8(5):654-63. doi: 10.1016/j.dnarep.2008.12.012. Epub 2009 Feb 10.

37.

Cloning and characterization of SARI (suppressor of AP-1, regulated by IFN).

Su ZZ, Lee SG, Emdad L, Lebdeva IV, Gupta P, Valerie K, Sarkar D, Fisher PB.

Proc Natl Acad Sci U S A. 2008 Dec 30;105(52):20906-11. doi: 10.1073/pnas.0807975106. Epub 2008 Dec 12.

38.

Coordinate 5' and 3' endonucleolytic trimming of terminally blocked blunt DNA double-strand break ends by Artemis nuclease and DNA-dependent protein kinase.

Yannone SM, Khan IS, Zhou RZ, Zhou T, Valerie K, Povirk LF.

Nucleic Acids Res. 2008 Jun;36(10):3354-65. doi: 10.1093/nar/gkn205. Epub 2008 Apr 25.

39.

Novel mode for neutrophil protease cathepsin G-mediated signaling: membrane shedding of epidermal growth factor is required for cardiomyocyte anoikis.

Rafiq K, Hanscom M, Valerie K, Steinberg SF, Sabri A.

Circ Res. 2008 Jan 4;102(1):32-41. Epub 2007 Nov 1.

PMID:
17975113
40.
41.
42.

Induction of a unique gene expression profile in primary human hepatocytes by hepatitis C virus core, NS3 and NS5A proteins.

Budhu A, Chen Y, Kim JW, Forgues M, Valerie K, Harris CC, Wang XW.

Carcinogenesis. 2007 Jul;28(7):1552-60. Epub 2007 Apr 2.

PMID:
17404395
43.

Radiation-induced cell signaling: inside-out and outside-in.

Valerie K, Yacoub A, Hagan MP, Curiel DT, Fisher PB, Grant S, Dent P.

Mol Cancer Ther. 2007 Mar;6(3):789-801. Review.

44.
45.

N-glycosylation of MDA-7/IL-24 is dispensable for tumor cell-specific apoptosis and "bystander" antitumor activity.

Sauane M, Gupta P, Lebedeva IV, Su ZZ, Sarkar D, Randolph A, Valerie K, Gopalkrishnan RV, Fisher PB.

Cancer Res. 2006 Dec 15;66(24):11869-77.

46.

Human chorionic gonadotropin modulates prostate cancer cell survival after irradiation or HMG CoA reductase inhibitor treatment.

Yacoub A, Hawkins W, Hanna D, Young H, Park MA, Grant M, Roberts JD, Curiel DT, Fisher PB, Valerie K, Grant S, Hagan MP, Dent P.

Mol Pharmacol. 2007 Jan;71(1):259-75. Epub 2006 Oct 18. Erratum in: Mol Pharmacol. 2016 Aug;90(2):151-2.

PMID:
17050804
47.

BiP/GRP78 is an intracellular target for MDA-7/IL-24 induction of cancer-specific apoptosis.

Gupta P, Walter MR, Su ZZ, Lebedeva IV, Emdad L, Randolph A, Valerie K, Sarkar D, Fisher PB.

Cancer Res. 2006 Aug 15;66(16):8182-91.

48.

Effect of hepatitis C virus core protein on the molecular profiling of human B lymphocytes.

Wu CG, Budhu A, Chen S, Zhou X, Popescu NC, Valerie K, Wang XW.

Mol Med. 2006 Jan-Mar;12(1-3):47-53.

49.

ErbB receptor tyrosine kinase network inhibition radiosensitizes carcinoma cells.

Contessa JN, Abell A, Valerie K, Lin PS, Schmidt-Ullrich RK.

Int J Radiat Oncol Biol Phys. 2006 Jul 1;65(3):851-8.

PMID:
16751066
50.

Molecular target-based therapy of pancreatic cancer.

Lebedeva IV, Sarkar D, Su ZZ, Gopalkrishnan RV, Athar M, Randolph A, Valerie K, Dent P, Fisher PB.

Cancer Res. 2006 Feb 15;66(4):2403-13.

Supplemental Content

Loading ...
Support Center